中文 | English
Bile duct cancer (cholangiocarcinoma) is a malignancy that arises from the cells lining the bile ducts, the tubes that carry bile from the liver and gallbladder to the small intestine. Although relatively rare, cholangiocarcinoma is an aggressive cancer that can be difficult to diagnose early. It is classified by location: intrahepatic (within the liver), perihilar/hilar (at the junction where bile ducts exit the liver, also called Klatskin tumor), and distal (near the small intestine).
Cholangiocarcinoma has shown increasing incidence worldwide over recent decades. In Asian populations, liver fluke infection is a significant risk factor, making awareness particularly important for our Flushing community. Other risk factors include primary sclerosing cholangitis, chronic hepatitis B/C, bile duct cysts, and hepatolithiasis (intrahepatic stones).
Dr. Jing Tong's expertise in therapeutic endoscopy, including ERCP with biliary stenting and EUS-guided tissue sampling, plays a crucial role in both diagnosis and palliative management of bile duct cancer. Early detection through advanced endoscopic techniques can significantly impact treatment outcomes.
Advanced training at a world-renowned center for biliary and pancreatic diseases.
Expert in therapeutic ERCP for biliary drainage, stent placement, and tissue sampling critical for cholangiocarcinoma management.
Compassionate communication in English, Mandarin, and Cantonese during a difficult diagnosis.
Coordination with surgeons, oncologists, and interventional radiologists for comprehensive cancer care.
Bile duct cancer is typically suspected when a patient develops painless jaundice. Diagnosis involves blood tests (CA 19-9), imaging (CT, MRI/MRCP), and tissue sampling via ERCP with brush cytology or EUS-guided biopsy. Advanced techniques like cholangioscopy can directly visualize the tumor.
ERCP is critical for both diagnosis and treatment. It allows tissue sampling for pathological diagnosis, biliary stent placement to relieve jaundice and itching, and can be used for photodynamic therapy. Dr. Tong's expertise in therapeutic ERCP is invaluable for these patients.
Surgical resection is the only potential cure, but only about 25-30% of cases are resectable at diagnosis. Select patients with early hilar cholangiocarcinoma may be candidates for liver transplant. For advanced cases, chemotherapy and endoscopic palliation can improve quality of life.
Liver fluke infections (Opisthorchis viverrini, Clonorchis sinensis), endemic in parts of East and Southeast Asia, are a major risk factor. Chronic hepatitis B, also more prevalent in Asian populations, is another contributing factor. This underscores the importance of screening in our community.
A biliary stent is a small tube placed during ERCP to keep the bile duct open when a tumor causes blockage. It relieves jaundice, itching, and the risk of infection. Stents may be plastic (temporary) or metal (longer-lasting) depending on the clinical situation.
Early diagnosis is critical. Contact Dr. Jing Tong for expert biliary evaluation.
